Nov 12,2014

Issue of First NovioSense Patent

NovioSense BV today announced the issuance by the European Patent Office of a patent that discloses a wireless flexible spring like sensor for detection of glucose levels in tear fluid. This invention contributes to the non-invasive near field communications (NFC) trend sweeping the medical device industry.

PRODUCT
View Analyst & Ambassador Comments
Go to original news
Nov 19,2014

Tandem Diabetes Care to Present at Piper Jaffray Healthcare Conference

Tandem Diabetes Care®, Inc. (Nasdaq:TNDM), a medical device company and manufacturer of the t:slim® Insulin Pump, today announced that Kim Blickenstaff, president and CEO, will present a company update at the Piper Jaffray Healthcare Conference in New York, NY. The presentation will take place on Wednesday, December 3, 2014 at 8:00am Eastern Time (5:00am Pacific Time).

CONFERENCES
View Analyst & Ambassador Comments
Go to original news
Nov 21,2014

Tandem Diabetes Care Announces Partnership with Tidepool to Further Expand Access to Diabetes Device Data

Tandem Diabetes Care®, Inc. (NASDAQ: TNDM), a medical device company and manufacturer of the t:slim® Insulin Pump, today announced a partnership with Tidepool, a non-profit dedicated to improving diabetes therapy management by offering an open source software platform that increases diabetes data accessibility. his partnership will enable users of the Tidepool Platform, which is currently under development, to download and access data from their t:slim Insulin Pump.

COLLABORATION PARTNERSHIP

#connected device

#insulin pump

View Analyst & Ambassador Comments
Go to original news
Nov 24,2014

Insulet Corporation to Present at Upcoming Investor Conferences

Insulet Corporation (NASDAQ: PODD), the leader in tubeless insulin pump technology with its OmniPod® Insulin Management System, plans to participate in the following upcoming investor conferences: The Piper Jaffray 26th Annual Healthcare Conference taking place at The New York Palace Hotel in New York City. Management is scheduled to present an overview of the Company on Tuesday, December 2, 2014 at 4:00 p.m. Eastern Time, and The Oppenheimer 25th Annual Healthcare Conference taking place at The Crowne Plaza Hotel in New York City. Management is scheduled to present an overview of the Company on Wednesday, December 10, 2014 at 9:45 a.m. Eastern Time.

CONFERENCES
View Analyst & Ambassador Comments
Go to original news
Dec 01,2014

Feasibility of overnight closed-loop therapy in young children with type 1 diabetes aged 3–6 years: comparison between diluted and standard insulin strength

The research aims to assess feasibility of overnight closed-loop therapy in young children with type 1 diabetes and contrast closed loop using diluted versus standard insulin strength. In this feasibility study, closed-loop therapy maintained good overnight glucose control with tendency towards reduced hypoglycemia and reduced glucose variability using diluted insulin.

CLINICAL STUDY

#closed loop

#cgm

#insulin pump

View Analyst & Ambassador Comments
Go to original news
Dec 01,2014

BD to Present at the 26th Annual Piper Jaffray Healthcare Conference

BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today that the company's presentation at the 26(th) Annual Piper Jaffray Healthcare Conference has been rescheduled to Wednesday, December 3, 2014, at 4:30 p.m. EST.

CONFERENCES
View Analyst & Ambassador Comments
Go to original news
May 25,2020

Bayer and WaveForm Technologies Inc. to Provide CGM Solutions for Patients in China

Bayer announced today a commercial agreement with WaveForm Technologies Inc. (WaveForm), a wholly owned subsidiary of AgaMatrix Holdings LLC and developer of novel products for continuous glucose monitoring (CGM) based in Wilsonville, Oregon, U.S. The collaboration aims to provide innovative glucose monitoring solutions to patients and physicians in China by integrating WaveForm’s novel and proprietary technologies with Bayer’s extensive experience and know-how in diabetes management. Under the terms of the agreement WaveForm will be responsible for obtaining marketing authorization for its Cascade CGM system while Bayer will be responsible for commercialization, distribution and sales, as well as customer support.

COLLABORATION PARTNERSHIP

#product & service

#cgm

View Analyst & Ambassador Comments
Go to original news
Jan 01,2022

Time in range, as measured by continuous glucose monitor, as a predictor of microvascular complications in type 2 diabetes: a systematic review

This review summarizes recent evidence supporting an association between CGM-derived TIR and microvascular complications among patients with T2DM.

CLINICAL STUDY

#cgm

View Analyst & Ambassador Comments
Go to original news
Jan 01,2022

Flash glucose monitoring in type 2 diabetes managed with basal insulin in the USA: a retrospective real-world chart review study and meta-analysis

This real-world study aimed to assess the impact on glycated hemoglobin (HbA1c) of flash glucose monitoring (FreeStyle Libre) use in adults with type 2 diabetes managed with basal insulin.

CLINICAL STUDY

#cgm

View Analyst & Ambassador Comments
Go to original news
Subscribe to DIABETES